223 related articles for article (PubMed ID: 37690972)
1. Actinium-225 Targeted Agents: Where Are We Now?
Mourtada F; Tomiyoshi K; Sims-Mourtada J; Mukai-Sasaki Y; Yagihashi T; Namiki Y; Murai T; Yang DJ; Inoue T
Brachytherapy; 2023; 22(6):697-708. PubMed ID: 37690972
[TBL] [Abstract][Full Text] [Related]
2. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract][Full Text] [Related]
3. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
4. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Thiele NA; Wilson JJ
Cancer Biother Radiopharm; 2018 Oct; 33(8):336-348. PubMed ID: 29889562
[TBL] [Abstract][Full Text] [Related]
5.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
6. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
Miederer M; Scheinberg DA; McDevitt MR
Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
[TBL] [Abstract][Full Text] [Related]
7. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
8. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
[TBL] [Abstract][Full Text] [Related]
9. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
10. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
12. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman D; Vatsa R; Sood A
Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
[TBL] [Abstract][Full Text] [Related]
14. Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225.
Castillo Seoane D; de Saint-Hubert M; Crabbe M; Struelens L; Koole M
Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):265-277. PubMed ID: 32441067
[TBL] [Abstract][Full Text] [Related]
15. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
16. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
17. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
Shi M; Jakobsson V; Greifenstein L; Khong PL; Chen X; Baum RP; Zhang J
Front Med (Lausanne); 2022; 9():1034315. PubMed ID: 36569154
[TBL] [Abstract][Full Text] [Related]
18. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies.
Abou DS; Zerkel P; Robben J; McLaughlin M; Hazlehurst T; Morse D; Wadas TJ; Pandya DN; Oyama R; Gaehle G; Nickels ML; Thorek DLJ
Cancer Biother Radiopharm; 2022 Jun; 37(5):355-363. PubMed ID: 35695807
[No Abstract] [Full Text] [Related]
19. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
